Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01630538
Recruitment Status : Active, not recruiting
First Posted : June 28, 2012
Last Update Posted : December 6, 2017
Information provided by (Responsible Party):
University of Manitoba